ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.08
-0.50 (-2.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.58
Open17.45
Bid0.00 x 900
Ask0.00 x 800
Day's Range17.03 - 17.58
52 Week Range14.51 - 41.20
Volume1,739,892
Avg. Volume3,324,473
Market Cap2.132B
Beta4.12
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.29
Trade prices are not sourced from all markets
  • Business Wire4 hours ago

    Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

    Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of persons and entities that acquired ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) securities between April 29, 2016 and July 9, 2018, inclusive (the “Class Period”), asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action. Investors suffering losses on their ACADIA investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights at 310-201-9150 or by email to shareholders@glancylaw.com, or visit the ACADIA case page on our website at www.glancylaw.com/case/acadia-pharmaceuticals-inc.

  • Business Wire8 hours ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or “the Company”) (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ACADIA shares fell more than 23% on April 9, 2018, after CNN reported that the Company’s Nuplazid treatment may have played a role in the death of patients receiving the treatment.

  • ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
    Business Wire9 hours ago

    ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that Austin D.

  • PR Newswire15 hours ago

    SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of ACADIA Pharmaceuticals Inc. (ACAD)

    NEW YORK , July 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc. ("Acadia" ...

  • ACCESSWIRE18 hours ago

    Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • PR Newswire2 days ago

    ACADIA Pharmaceuticals, Inc. (ACAD) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

    BOSTON , July 18, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether ACADIA Pharmaceuticals, Inc. ("ACADIA" ...

  • ACCESSWIRE2 days ago

    Today's Research Reports on Stocks to Watch: AVEO Pharmaceuticals and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Shares of AVEO Pharmaceuticals were deep in the red on Tuesday after a SEC 8-K revealed that the company’s TIVO-3 data is now delayed until the fourth quarter. Shares of ACADIA Pharmaceuticals were in the green despite any news. AVEO Pharmaceuticals, Inc. shares closed down 24.21% on Tuesday with nearly 9.4 million shares traded.

  • Business Wire2 days ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“ACADIA” or ''the Company'') (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ACADIA shares fell more than 23% on April 9, 2018, after CNN reported that the Company’s Nuplazid treatment may have played a role in the death of patients receiving the treatment.

  • Business Wire2 days ago

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against ACADIA Pharmaceuticals Inc. – ACAD

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ACADIA Pharmaceuticals Inc. resulting from allegations that ACADIA may have issued materially misleading business information to the investing public.

  • Business Wire3 days ago

    Glancy Prongay & Murray LLP Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

    Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • Business Wire4 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors

    Law Offices of Howard G. Smith continues its investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 26. Over the last one-month, outflows of investor capital in ETFs holding ACAD totaled $2.13 billion.

  • Business Wire6 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

    Glancy Prongay & Murray LLP (“GPM”) announces that it has commenced an investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • 5 Big Pharma Stocks Investors Love Right Now
    InvestorPlace7 days ago

    5 Big Pharma Stocks Investors Love Right Now

    News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.

  • Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
    Motley Fool7 days ago

    Better Buy: Acadia Pharmaceuticals vs. Eli Lilly

    Which stock wins in a battle between a small, beaten-down biotech and an established major drugmaker?

  • PR Newswire8 days ago

    Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm's Investigation of Possible Disclosure Violations

    SAN FRANCISCO , July 11, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to the firm's investigation of possible securities law violations.  ...

  • Business Wire10 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors

    Law Offices of Howard G. Smith announces an investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors concerning the Company and its officers’ possible violations of federal securities laws. On April 9, 2018, CNN reported that “[p]hysicians, medical researchers and other experts told CNN that they worried that [Nuplazid] had been approved too quickly, based on too little evidence that it was safe or effective.” On this news, ACADIA’s share price fell more than 23% on April 9, 2018, thereby injuring investors. Then, on April 25, 2018, CNN reported that the U.S. Food and Drug Administration was re-examining the safety of Nuplazid, which was approved “despite concerns that not enough was known about the drug’s risks.” On this news, ACADIA’s share price fell nearly 22% on April 25, 2018, thereby further injuring investors.

  • InvestorPlace10 days ago

    Why ACADIA Pharmaceuticals Stock Is Falling Today

    ACADIA Pharmaceuticals (NASDAQ:ACAD) stock fell more than 6% on Monday as one of the company’s drugs is being investigated for its efficacy.

  • GlobeNewswire10 days ago

    Bragar Eagel & Squire, P.C. is Investigating ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, July 09, 2018-- Bragar Eagel & Squire, P.C. is investigating potential claims against ACADIA Pharmaceuticals Inc.. Our investigation concerns whether ACADIA violated the federal securities laws ...

  • GlobeNewswire10 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of ACADIA Pharmaceuticals Inc.

    NEW YORK, July 09, 2018-- Levi & Korsinsky announces it has commenced an investigation of ACADIA Pharmaceuticals Inc. concerning possible violations of federal securities laws.. On April 9, 2018, ACADIA ...

  • ACCESSWIRE11 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Ionis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...

  • The 3 Worst Biotech Stocks of 2018 (So Far)
    Motley Fool12 days ago

    The 3 Worst Biotech Stocks of 2018 (So Far)

    These biotech stocks have taken a beating this year. But are any of them ready to rebound?

  • Exploring Acadia Pharmaceuticals’ Promising Research Pipeline
    Market Realist14 days ago

    Exploring Acadia Pharmaceuticals’ Promising Research Pipeline

    Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis. The company believes that it has the potential to avoid many of the side effects of existing antipsychotics, none of which have been approved by the FDA. Acadia Pharmaceuticals also believes that the drug can potentially address key medical needs in neuropsychological and psychiatric disorders in addition to Parkinson’s disease psychosis.

  • Here’s Why Analysts See a Major Upside in Acadia Pharmaceuticals
    Market Realist14 days ago

    Here’s Why Analysts See a Major Upside in Acadia Pharmaceuticals

    Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company engaged in developing and bringing to market innovative medicines targeted at central nervous system disorders. Of the eight analysts covering Acadia Pharmaceuticals in July, seven have given the stock “buy” or higher recommendations, while one has given it a “hold” rating. The mean rating for the stock is 2, and its target price is $47.29, implying a potential upside of 193% over the stock’s trading price of $16.13 on July 2.

  • Analyzing the Financial Performance of Acadia Pharmaceuticals
    Market Realist14 days ago

    Analyzing the Financial Performance of Acadia Pharmaceuticals

    This increase was due to the 120% volume growth of Nuplazid sales aided by the higher selling price of the drug. For 2018 and 2019, Acadia Pharmaceuticals is expected to report revenues of $261.41 million and $421.44 million, respectively. The cost of sales incurred by Acadia Pharmaceuticals fell marginally from $2.26 million in Q1 2017 to $2.15 million in Q1 2018 due to higher manufacturing levels.